Your browser is no longer supported. Please, upgrade your browser.
Settings
IMGN ImmunoGen, Inc. daily Stock Chart
IMGN [NASD]
ImmunoGen, Inc.
Index- P/E- EPS (ttm)-1.21 Insider Own0.90% Shs Outstand147.37M Perf Week-9.56%
Market Cap362.53M Forward P/E- EPS next Y-1.01 Insider Trans-7.96% Shs Float146.97M Perf Month0.00%
Income-168.80M PEG- EPS next Q-0.21 Inst Own84.70% Short Float7.57% Perf Quarter-51.09%
Sales53.40M P/S6.79 EPS this Y-23.20% Inst Trans0.64% Short Ratio3.21 Perf Half Y-69.29%
Book/sh0.07 P/B35.14 EPS next Y10.10% ROA-52.70% Target Price6.38 Perf Year-75.86%
Cash/sh1.78 P/C1.38 EPS next 5Y- ROE-609.90% 52W Range2.27 - 12.31 Perf YTD-48.75%
Dividend- P/FCF- EPS past 5Y-7.60% ROI- 52W High-80.02% Beta2.21
Dividend %- Quick Ratio3.90 Sales past 5Y-2.30% Gross Margin- 52W Low8.37% ATR0.15
Employees296 Current Ratio3.90 Sales Q/Q-66.00% Oper. Margin- RSI (14)30.32 Volatility6.04% 5.72%
OptionableYes Debt/Eq0.19 EPS Q/Q-170.00% Profit Margin- Rel Volume0.86 Prev Close2.53
ShortableYes LT Debt/Eq0.19 EarningsMay 10 BMO Payout- Avg Volume3.47M Price2.46
Recom2.40 SMA20-7.20% SMA50-30.59% SMA200-61.78% Volume2,993,985 Change-2.77%
Mar-19-19Downgrade JP Morgan Neutral → Underweight
Mar-05-19Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-04-19Downgrade SVB Leerink Outperform → Mkt Perform
Mar-04-19Downgrade H.C. Wainwright Buy → Neutral $18 → $3.50
Mar-01-19Downgrade Piper Jaffray Overweight → Neutral $13 → $2.50
Mar-01-19Downgrade Jefferies Buy → Hold
Sep-07-18Initiated Piper Jaffray Overweight
Feb-08-18Resumed RBC Capital Mkts Outperform $12
Jan-31-18Initiated H.C. Wainwright Buy $18
Jul-06-17Upgrade RBC Capital Mkts Sector Perform → Outperform $5 → $12
Apr-19-17Upgrade Leerink Partners Mkt Perform → Outperform
Apr-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $18 → $7
Feb-01-16Reiterated RBC Capital Mkts Outperform $19 → $18
Nov-25-15Upgrade Jefferies Hold → Buy
Sep-21-15Downgrade Morgan Stanley Equal-Weight → Underweight
Aug-03-15Downgrade Cantor Fitzgerald Buy → Hold
Jul-29-15Reiterated Oppenheimer Outperform $13 → $24
Jul-27-15Reiterated RBC Capital Mkts Outperform $15 → $20
Jun-08-15Reiterated Leerink Partners Mkt Perform $9 → $15
Jun-01-15Upgrade Morgan Stanley Underweight → Equal-Weight
Apr-18-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results Business Wire
Apr-15-19 01:49PM  ImmunoGen Stock Is in Trouble Going Into Earnings InvestorPlace
Apr-08-19 05:16PM  Here's Why ImmunoGen Tumbled 43% in March Motley Fool
Mar-26-19 03:48PM  Do Directors Own ImmunoGen, Inc. (NASDAQ:IMGN) Shares? Simply Wall St.
Mar-12-19 08:56AM  Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock Zacks
Mar-10-19 09:30AM  ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound? Zacks
Mar-06-19 12:22PM  ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates GuruFocus.com
12:05PM  Four Biotech Stocks Setting The Standard on Wednesday ACCESSWIRE
10:26AM  Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More Zacks
Mar-04-19 11:38PM  Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks Zacks
Mar-02-19 12:48PM  Immunogen Inc (IMGN) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-01-19 01:45PM  Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint TheStreet.com -46.82%
12:13PM  Why ImmunoGen Stock Is Crashing Today Motley Fool
08:08AM  Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail American City Business Journals
06:51AM  Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint MarketWatch
06:38AM  ImmunoGen's ovarian cancer drug fails in late-stage study Reuters
06:30AM  ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer Business Wire
Feb-27-19 05:14PM  Why ImmunoGen Tumbled 20.3% Today Motley Fool -20.28%
04:31PM  ImmunoGen Announces Multiple Presentations at AACR Annual Meeting Business Wire
Feb-22-19 07:40AM  Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries New Research Emphasizes Economic Growth GlobeNewswire
Feb-21-19 08:00AM  Healthcare Companies Investors are Watching ACCESSWIRE
Feb-18-19 02:19PM  How ImmunoGen, Inc. (NASDAQ:IMGN) Could Add Value To Your Portfolio Simply Wall St.
Feb-12-19 07:15PM  Edited Transcript of IMGN earnings conference call or presentation 8-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -7.43%
03:58PM  ImmunoGen Still Waiting to Take Its Leap "Forward" Motley Fool
Feb-11-19 09:29AM  ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up Zacks
08:53AM  Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock Zacks
Feb-08-19 09:35PM  ImmunoGen (IMGN) Q4 2018 Earnings Conference Call Transcript Motley Fool +10.31%
07:45AM  ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:47AM  ImmunoGen: 4Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and 2018 Operating Results Business Wire
Feb-06-19 06:35PM  Why ImmunoGen Jumped Almost 14% Today Motley Fool +13.66%
Feb-01-19 10:30AM  Earnings Preview: ImmunoGen (IMGN) Q4 Earnings Expected to Decline Zacks
Jan-24-19 04:30PM  ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results Business Wire
Jan-18-19 03:00PM  Have Insiders Been Selling ImmunoGen, Inc. (NASDAQ:IMGN) Shares This Year? Simply Wall St.
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 04:01PM  ImmunoGen Announces Sale of Residual Kadcyla Royalties Business Wire
Jan-07-19 05:20PM  Why ImmunoGen Jumped Today Motley Fool +10.53%
Jan-02-19 08:30AM  ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-26-18 04:18PM  Why ImmunoGen Shot Up 13% Today Motley Fool +13.07%
Dec-17-18 09:52PM  Hedge Funds Are Betting On ImmunoGen, Inc. (IMGN) Insider Monkey
Dec-12-18 07:55AM  Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Dec-06-18 02:49PM  Roche's Kadcyla Halves Death Risk in Breast Cancer Study Zacks
Dec-02-18 05:51PM  The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs Benzinga
09:30AM  ImmunoGen (IMGN) Down 7.2% Since Last Earnings Report: Can It Rebound? Zacks
Dec-01-18 10:31AM  ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting Business Wire
Nov-27-18 07:32AM  The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial Benzinga -8.20%
Nov-26-18 04:47PM  Former Aveo exec resigns as ImmunoGen CFO after fraud verdict American City Business Journals
04:01PM  ImmunoGen Announces Resignation of Chief Financial Officer Business Wire
Nov-25-18 09:41AM  The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings Benzinga
Nov-21-18 11:23AM  Former Aveo CFO misled biotech's investors, jury finds American City Business Journals
Nov-20-18 08:31AM  Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? Zacks
Nov-19-18 07:31AM  Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT Thomson Reuters StreetEvents -7.36%
Nov-14-18 11:35AM  Healthcare Stocks with Turnaround Potential ACCESSWIRE
Nov-09-18 02:12PM  ImmunoGen Waits to Leap "Forward" Motley Fool
Nov-07-18 08:28PM  Here's Why ImmunoGen Closed Almost 12% Up on Wednesday Motley Fool +11.98%
09:46AM  Here's Why ImmunoGen Shares Lost 42.7% in October Motley Fool
08:20AM  Report: Developing Opportunities within TE Connectivity, EnPro Industries, Innophos, Ameren, ImmunoGen, and ICF International Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-06-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
Nov-05-18 11:01AM  How ImmunoGen Inc (NASDAQ:IMGN) Can Impact Your Portfolio Volatility Simply Wall St.
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
Nov-02-18 12:12PM  Immunogen Inc (IMGN) Q3 2018 Earnings Conference Call Transcript Motley Fool
10:43AM  MARKETS: Today's job numbers might have been too good and could spook stocks Yahoo Finance Video
09:40AM  ImmunoGen (IMGN) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:36AM  ImmunoGen: 3Q Earnings Snapshot Associated Press
06:30AM  ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results Business Wire
Nov-01-18 02:55PM  Q3 Earnings Outlook For ImmunoGen Benzinga +9.39%
09:01AM  ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting Business Wire
Oct-26-18 10:30AM  ImmunoGen (IMGN) Q3 Earnings Preview: What to Look Out For Zacks
Oct-22-18 11:05AM  Here's Why ImmunoGen Fell Today Motley Fool -16.02%
Oct-20-18 06:30AM  ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress Business Wire
Oct-18-18 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results Business Wire
Oct-15-18 10:30AM  Cancer Companies to Watch ACCESSWIRE
Oct-14-18 01:21PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Oct-10-18 08:30AM  Report: Developing Opportunities within Southwest Airlines, Select Income REIT, Oxford Industries, ImmunoGen, Navigant Consulting, and TrueBlue Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 06:05PM  ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO Business Wire
09:50AM  Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock? Zacks
Oct-05-18 05:00PM  Why ImmunoGen Inc. Dropped 8% Today Motley Fool -9.00%
Oct-04-18 05:53PM  Why ImmunoGen, Inc. Fell 10.6% on Thursday Motley Fool -10.62%
Sep-24-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire
Sep-19-18 08:31AM  Who Owns Most Of ImmunoGen Inc (NASDAQ:IMGN)? Simply Wall St.
Aug-27-18 04:30PM  ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire +6.60%
Aug-06-18 07:45AM  Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble Discovering Underlying Factors of Influence GlobeNewswire
Jul-31-18 04:30PM  ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference Business Wire
04:06PM  ImmunoGen's Investors Play the Waiting Game Motley Fool
Jul-30-18 11:09AM  Edited Transcript of IMGN earnings conference call or presentation 27-Jul-18 12:00pm GMT Thomson Reuters StreetEvents
10:16AM  ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates Zacks
Jul-27-18 07:50AM  ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates Zacks
06:58AM  ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss Zacks
06:30AM  ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results Business Wire
06:00AM  ImmunoGen, Inc. to Host Earnings Call ACCESSWIRE
Jul-26-18 02:59PM  Immunogen Earnings Preview Benzinga
Jul-25-18 11:28AM  What's in Store for ImmunoGen (IMGN) This Earnings Season? Zacks
Jul-13-18 02:33PM  Here's Why ImmunoGen Fell 15.1% in June Motley Fool
Jul-12-18 04:30PM  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results Business Wire
Jun-26-18 08:05AM  Better Buy: Exelixis, Inc. vs. Immunogen, Inc. Motley Fool
Jun-22-18 07:30AM  Free Technical Research on ImmunoGen and Three More Biotech Equities ACCESSWIRE
Jun-21-18 08:15AM  ImmunoGen Announces Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Jun-19-18 09:41AM  ImmunoGen's Lead Candidate Gets Fast Track for Ovarian Cancer Zacks
Jun-18-18 08:00AM  ImmunoGen Announces FDA Fast Track Designation for Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer Business Wire
Jun-11-18 04:05PM  ImmunoGen Announces Closing of Public Offering of Common Stock Business Wire
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory Richard J.Executive VP & CSOJan 07Sale5.273,03816,014236,056Jan 08 08:47 AM
Goldberg Mark AlanDirectorNov 06Buy5.7630,000172,80053,800Nov 07 09:54 AM
Berkenblit AnnaVP & Chief Medical OfficerOct 16Sale8.005,85146,808132,769Oct 17 09:51 AM
Berkenblit AnnaVP & Chief Medical OfficerSep 10Sale9.465,85155,350138,620Sep 11 05:20 PM
Johnston David BrannonChief Financial OfficerJun 06Option Exercise3.0510,00030,500190,690Jun 08 04:08 PM
Johnston David BrannonChief Financial OfficerJun 06Sale11.0210,000110,200180,690Jun 08 04:08 PM